Fotivda
Payments companies reported to CMS as associated with Fotivda. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fotivda, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fotivda
These are the largest totals companies reported as associated with Fotivda. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Amit Mehta | Cary, NC | Hematology & Oncology | $121,932.24 |
| Hardeep Phull | Escondido, CA | Hematology & Oncology | $115,383.42 |
| Deepak Kilari | Milwaukee, WI | Hematology & Oncology | $78,966.35 |
| Alan Tan | Nashville, TN | Hematology & Oncology | $69,568.92 |
| Asad Dean | Fort Worth, TX | Hematology & Oncology | $50,478.98 |
| Randy Sweis | Chicago, IL | Hematology & Oncology | $29,670.16 |
| Alfredo Torres | Port Jefferson Station, NY | Hematology & Oncology | $28,236.26 |
| Thomas Hutson | Dallas, TX | Medical Oncology | $24,899.24 |
| David Gill | Murray, UT | Medical Oncology | $18,931.66 |
| Michael Lattanzi | Austin, TX | Hematology & Oncology | $17,706.18 |
Prescribed Fotivda?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.